PMID- 12000210
OWN - NLM
STAT- MEDLINE
DCOM- 20020531
LR  - 20190901
IS  - 0160-6689 (Print)
IS  - 0160-6689 (Linking)
VI  - 63
IP  - 4
DP  - 2002 Apr
TI  - An open-label study of naltrexone in the treatment of kleptomania.
PG  - 349-56
AB  - BACKGROUND: The present study was designed to test the short-term efficacy and 
      safety of naltrexone in the treatment of kleptomania. METHOD: 10 subjects (7 
      women, 3 men) who fulfilled DSM-IV criteria for kleptomania and were free from 
      other Axis I diagnoses by the Structured Clinical Interview for DSM-IV screening 
      participated in a 12-week naltrexone open-label trial. Kleptomania symptom change 
      was assessed with the Clinical Global Impressions scale (both severity and 
      improvement measures), Sheehan Disability Scale (SDS), Global Assessment of 
      Functioning (GAF), and Kleptomania Symptom Assessment Scale. Side effects were 
      monitored weekly, and liver function tests were administered every 2 weeks. 
      RESULTS: Naltrexone reduced urges to steal and stealing behavior. Subjects showed 
      significant improvement (p < .005) over the 11-week treatment period in all 
      measures compared with measures taken at baseline. Seven subjects (70.0%) were 
      very much improved and 2 (20.0%) were much improved at study end. Subjects also 
      reported overall significant improvement in social and occupational functioning 
      as determined by both the GAF and the SDS (p < .000). Men responded to naltrexone 
      as well as women. The mean naltrexone dose required for effective symptom control 
      was 145 mg/day. Nausea was common during the first week of treatment. Five 
      subjects (50.0%) reported previous trials of medication and cognitive-behavioral 
      therapy without any effect on kleptomania symptoms. CONCLUSION: The present 
      findings provide evidence that naltrexone may be effective in the treatment of 
      kleptomania. The present report is preliminary. Further studies are needed to 
      confirm these findings.
FAU - Grant, Jon E
AU  - Grant JE
AD  - Department of Psychiatry, University of Minnesota Medical School, Minneapolis 
      55454-1495, USA. grant045@umn.edu
FAU - Kim, Suck Won
AU  - Kim SW
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PL  - United States
TA  - J Clin Psychiatry
JT  - The Journal of clinical psychiatry
JID - 7801243
RN  - 0 (Narcotic Antagonists)
RN  - 0 (Placebos)
RN  - 5S6W795CQM (Naltrexone)
SB  - IM
MH  - Adult
MH  - Ambulatory Care
MH  - Disruptive, Impulse Control, and Conduct Disorders/diagnosis/*drug 
      therapy/psychology
MH  - Drug Administration Schedule
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Naltrexone/administration & dosage/*therapeutic use
MH  - Narcotic Antagonists/administration & dosage/*therapeutic use
MH  - Placebos
MH  - Psychiatric Status Rating Scales/statistics & numerical data
MH  - Reproducibility of Results
MH  - Severity of Illness Index
MH  - Sex Factors
MH  - Single-Blind Method
MH  - Treatment Outcome
EDAT- 2002/05/10 10:00
MHDA- 2002/06/01 10:01
CRDT- 2002/05/10 10:00
PHST- 2002/05/10 10:00 [pubmed]
PHST- 2002/06/01 10:01 [medline]
PHST- 2002/05/10 10:00 [entrez]
AID - 10.4088/jcp.v63n0413 [doi]
PST - ppublish
SO  - J Clin Psychiatry. 2002 Apr;63(4):349-56. doi: 10.4088/jcp.v63n0413.